Summary
Moderna and Merck announced that a new personalized mRNA vaccine significantly reduced the risk of melanoma recurrence and spread in a late-stage trial, marking a major advancement in cancer treatment.
New mRNA Vaccine Could Prevent Skin Cancer Recurrence, Companies Announce
HyperFast News
Related news
mRNA Cancer Vaccine Succeeded in Phase 3 Melanoma Trial, Moderna and Merck Say
20 Sept 2026, 7:23 pm · News
Moderna and Merck's mRNA Cancer Vaccine Shows Promising Results for Melanoma
20 Sept 2026, 7:23 pm · News
Moderna's mRNA Technology Expands to Flu Vaccine with FDA Approval of mFlusiva
20 Sept 2026, 7:23 pm · News
